Glenmark Gets Early Win In Challenge To Merck's Zetia Patent Claims
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Phrmaceuticals has won a favorable decision in a U.S. court against Merck and its patents on Zetia (ezetimibe) for controlling cholesterol
You may also be interested in...
Risk, Reward Sharing Extends To Generics: Glenmark, Par Tango As Lanuch Prospects For Zetia Copies Brighten
MUMBAI - Its raining deals for the Indian drug maker Glenmark. A day after the $450 million generics-cum-innovation driven pharma signed an out-licensing agreement with Sanofi Aventis for a novel research compound in pain management, it has now announced another one-of-its-kind licensing agreement - this time with Par Pharma to market generic versions of Merck/Schering Plough's $1.4 billion cholesterol drug Zetia (ezetimibe) in the United States
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.